Literature DB >> 14963160

Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses.

Stefan Worgall1, Annette Busch, Michael Rivara, David Bonnyay, Philip L Leopold, Robert Merritt, Neil R Hackett, Peter W Rovelink, Joseph T Bruder, Thomas J Wickham, Imi Kovesdi, Ronald G Crystal.   

Abstract

Adenovirus (Ad) gene transfer vectors can be used to transfer and express antigens and function as strong adjuvants and thus are useful platforms for the development of genetic vaccines. Based on the hypothesis that Ad vectors with enhanced infectibility of dendritic cells (DC) may be able to evoke enhanced immune responses against antigens encoded by the vector in vivo, the present study analyzes the vaccine potential of an Ad vector expressing beta-galactosidase as a model antigen and genetically modified with RGD on the fiber knob [AdZ.F(RGD)] to more selectively infect DC and consequently enhance immunity against the beta-galactosidase antigen. Infection of murine DC in vitro with AdZ.F(RGD) showed an eightfold-increased transgene expression following infection compared to AdZ (also expressing beta-galactosidase, but with a wild-type capsid). Binding, cellular uptake, and trafficking in DC were also increased with AdZ.F(RGD) compared to AdZ. To determine whether AdZ.F(RGD) could evoke enhanced immune responses to beta-galactosidase in vivo, C57BL/6 mice were immunized with AdZ.F(RGD) or AdZ subcutaneously via the footpad. Humoral responses with both vectors were comparable, with similar anti-beta-galactosidase antibody levels following vector administration. However, cellular responses to beta-galactosidase were significantly enhanced, with the frequency of CD4(+) as well as the CD8(+) beta-galactosidase-specific gamma interferon response in cells isolated from the draining lymph nodes increased following immunization with AdZ.F(RGD) compared to Ad.Z (P < 0.01). Importantly, this enhanced cellular immune response of the AdZ.F(RGD) vector was sufficient to evoke enhanced inhibition of the growth of preexisting tumors expressing beta-galactosidase: BALB/c mice implanted with the CT26 syngeneic beta-galactosidase-expressing colon carcinoma cell line and subsequently immunized with AdZ.F(RGD) showed decreased tumor growth and improved survival compared to mice immunized with AdZ. These data demonstrate that addition of an RGD motif to the Ad fiber knob increases the infectibility of DC and leads to enhanced cellular immune responses to the Ad-transferred transgene, suggesting that the RGD capsid modification may be useful in developing Ad-based vaccines.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14963160      PMCID: PMC369215          DOI: 10.1128/jvi.78.5.2572-2580.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

Review 1.  Th1 and Th2 cells.

Authors:  C Dong; R A Flavell
Journal:  Curr Opin Hematol       Date:  2001-01       Impact factor: 3.284

Review 2.  Immunobiology of dendritic cells.

Authors:  J Banchereau; F Briere; C Caux; J Davoust; S Lebecque; Y J Liu; B Pulendran; K Palucka
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

Review 3.  DNA vaccines: immunology, application, and optimization*.

Authors:  S Gurunathan; D M Klinman; R A Seder
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

4.  Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy.

Authors:  N Mittereder; K L March; B C Trapnell
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

5.  Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein.

Authors:  I Kirby; E Davison; A J Beavil; C P Soh; T J Wickham; P W Roelvink; I Kovesdi; B J Sutton; G Santis
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

6.  Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells.

Authors:  K S Denis-Mize; M Dupuis; M L MacKichan; M Singh; B Doe; D O'Hagan; J B Ulmer; J J Donnelly; D M McDonald; G Ott
Journal:  Gene Ther       Date:  2000-12       Impact factor: 5.250

7.  Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae.

Authors:  P W Roelvink; G Mi Lee; D A Einfeld; I Kovesdi; T J Wickham
Journal:  Science       Date:  1999-11-19       Impact factor: 47.728

8.  Modifications of the fiber in adenovirus vectors increase tropism for malignant glioma models.

Authors:  M J Staba; T J Wickham; I Kovesdi; D E Hallahan
Journal:  Cancer Gene Ther       Date:  2000-01       Impact factor: 5.987

9.  Development of a preventive vaccine for Ebola virus infection in primates.

Authors:  N J Sullivan; A Sanchez; P E Rollin; Z Y Yang; G J Nabel
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

10.  Adenovirus vector-mediated gene transfer to regional lymph nodes.

Authors:  D Labow; S Lee; R J Ginsberg; R G Crystal; R J Korst
Journal:  Hum Gene Ther       Date:  2000-03-20       Impact factor: 5.695

View more
  31 in total

Review 1.  A realistic chance for gene therapy in the near future.

Authors:  Stefan Worgall
Journal:  Pediatr Nephrol       Date:  2004-11-10       Impact factor: 3.714

2.  Fiber and penton base capsid modifications yield diminished adenovirus type 5 transduction and proinflammatory gene expression with retention of antigen-specific humoral immunity.

Authors:  John W Schoggins; Erik Falck-Pedersen
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

3.  Recombinant adenovirus type 5 vectors that target DC-SIGN, ChemR23 and alpha(v)beta3 integrin efficiently transduce human dendritic cells and enhance presentation of vectored antigens.

Authors:  Casey A Maguire; Ramil Sapinoro; Natasha Girgis; Sol M Rodriguez-Colon; Servio H Ramirez; Jennifer Williams; Stephen Dewhurst
Journal:  Vaccine       Date:  2005-08-24       Impact factor: 3.641

4.  Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity.

Authors:  Anja Krause; Ju H Joh; Neil R Hackett; Peter W Roelvink; Joseph T Bruder; Thomas J Wickham; Imre Kovesdi; Ronald G Crystal; Stefan Worgall
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

5.  Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: implications for clinical efficacy.

Authors:  Matthieu Perreau; Franck Mennechet; Nicolas Serratrice; Joel N Glasgow; David T Curiel; Harald Wodrich; Eric J Kremer
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

Review 6.  Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach.

Authors:  Qiana L Matthews
Journal:  Mol Pharm       Date:  2010-12-01       Impact factor: 4.939

7.  miRNA-mediated silencing in hepatocytes can increase adaptive immune responses to adenovirus vector-delivered transgenic antigens.

Authors:  Matthias W Kron; Sigrid Espenlaub; Tatjana Engler; Reinhold Schirmbeck; Stefan Kochanek; Florian Kreppel
Journal:  Mol Ther       Date:  2011-05-10       Impact factor: 11.454

Review 8.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

9.  Post-exposure immunization by capsid-modified AdC7 vector expressing Pseudomonas aeruginosa OprF clears P. aeruginosa respiratory infection.

Authors:  Rika Gomi; Anurag Sharma; Wenzhu Wu; Biin Sung; Stefan Worgall
Journal:  Vaccine       Date:  2017-11-07       Impact factor: 3.641

10.  GammadeltaT cells initiate acute inflammation and injury in adenovirus-infected liver via cytokine-chemokine cross talk.

Authors:  Maureen N Ajuebor; Yijun Jin; Griffin L Gremillion; Robert M Strieter; Qingling Chen; Patrick A Adegboyega
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.